Overexpression of AMACR - at both mRNA and protein levels - has been reported in cancerous prostatic tissue when compared to benign prostatic hyperplasia (BPH) and normal prostate tissue [4, 10–14]. Here, AMACR is linked to benign prostatic hyperplasia.